articleJournal of the American College of CardiologyMar 6, 2023HYBRID OA

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616

CMChristie M. BallantynePBPuja BankaGMGustavo MéndezRGRaymundo GarciaJRJulio Rosenstock

Baylor College of Medicine · Merck & Co., Inc., Rahway, NJ, USA (United States) · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia.

Objectives

This Phase 2b, randomized, double-blind, placebo-controlled, multicenter trial aimed to evaluate the efficacy and safety of MK-0616 in participants with hypercholesterolemia.

Citation impact

184
total citations
FWCI
54.94
Percentile
100%
References
30
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Medicine
  • Placebo
  • PCSK9
  • Internal medicine
  • Adverse effect
  • Randomized controlled trial
  • Gastroenterology
  • Cholesterol
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding